Longevity.Technology UNLOCKED

Longevity.Technology

Longevity.Technology UNLOCKED brings together science, business, and human potential to explore the frontier of longer, healthier living. 🎙 Mondays: In-depth conversations with scientists, founders, investors, operators, and elite performers shaping the longevity ecosystem. 🧠 Fridays: A sharp weekly round-up of the biggest stories, trends, and insights from across the longevity space. If you’re curious about the future of health, performance, and lifespan, this is where it gets UNLOCKED.

  1. 6h ago

    One-Shot Gene Therapies & Peptides | Longevity News Roundup—Week 31, 2026

    Hosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities. Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off. Link: rechargehealthas.sjv.io/jRQyQ5 ---------- In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine new Alzheimer's therapies, the growing debate around experimental peptides, expanding access to investigational treatments, rapid advances in metabolic disease and encouraging progress in longevity gene therapy. Voyager Therapeutics reported that its investigational gene therapy VY1706 reduced tau protein by up to 75% in non-human primates for six months after a single intravenous dose, using a novel blood-brain barrier delivery approach.An advisory panel to the US Food and Drug Administration recommended broader access to compounded wellness peptides despite concerns over limited human evidence, highlighting the growing tension between consumer demand, regulatory oversight and the need for robust clinical trials.Vandria announced that its oral mitochondrial therapy VNA-318  safely reached the brain in its first human study, supporting once-daily dosing ahead of planned Alzheimer's trials.Montana advanced Right to Try legislation that could expand patient access to investigational therapies beyond traditional approval pathways, raising new questions about evidence, transparency and responsible implementation.D&D Pharmatech reported that its once-weekly dual GLP-1/glucagon receptor agonist zabopegdutide rapidly reduced liver fat and stiffness, with benefits seen even among participants who experienced minimal weight loss.Genflow Biosciences reported positive early results from its SIRT6 gene therapy trial in aging dogs, supporting the growing use of companion animals as a bridge toward future human longevity therapies ---------- News & References: Voyager’s single-dose gene therapy cuts tau by 75% → https://longevity.technology/news/voyagers-single-dose-gene-therapy-cuts-tau-by-75/FDA panel backs peptides over its own scientists → https://longevity.technology/news/fda-panel-backs-peptides-over-its-own-scientists/Vandria’s experimental Alzheimer’s pill proves safe, reaches target in first human study → https://longevity.technology/news/vandrias-experimental-alzheimers-pill-proves-safe-reaches-target-in-first-human-study/Montana takes next step on experimental therapies → https://longevity.technology/news/montana-takes-next-step-on-experimental-therapies/Zabopegdutide shows rapid, weight-independent liver benefits in Phase 2 → https://longevity.technology/news/zabopegdutide-shows-rapid-weight-independent-liver-benefits-in-phase-2/Genflow reports positive early results in aging-dog gene therapy trial → https://longevity.technology/news/genflow-reports-positive-early-results-in-aging-dog-gene-therapy-trial/

  2. 4d ago

    Can Longevity Become Public Policy?

    Hosts: Phil Newman: ⁠https://qrco.de/bgXpNY⁠ Nina Patrick: ⁠⁠⁠https://qrco.de/bgXpKn⁠ ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities. Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off. Link: ⁠rechargehealthas.sjv.io/jRQyQ5⁠ ---------- Guests: Dylan V. Livingston Founder and CEO of The Alliance for Longevity Initiatives (A4LI) LinkedIn: ⁠www.linkedin.com/in/dylan-v-livingston/⁠ Website: ⁠a4li.org/⁠ ---------- What if the biggest barrier to longer, healthier lives isn't scientific discovery, but public policy? In this episode, Phil Newman and Dr. Nina Patrick sit down with Dylan V. Livingston, founder and CEO of the Alliance for Longevity Initiatives (A4LI), to explore how Washington is becoming one of the most important frontiers in healthy aging. Based on his unusual journey from political campaigning to longevity advocacy, Dylan explains why extending healthy lifespan requires more than innovative biotechnology. It also requires regulatory reform, stronger public investment, and policymakers who understand the biology of aging. From his work advancing state-level Right to Try legislation to proposals for new FDA pathways that recognize therapies targeting multiple age-related diseases, he shares how policy could dramatically accelerate the translation of longevity science into clinical practice. The conversation explores the growing role of biomarkers, surrogate endpoints, and ARPA-H's PROSPR program in creating clearer regulatory pathways for aging interventions. Dylan also discusses proposals for expanding NIH support for aging biology research, why the current funding landscape remains misaligned with the burden of age-related disease, and how advocacy organizations can help bridge the gap between researchers, biotech companies, regulators, and elected officials. They also examine whether the United States can maintain its leadership in longevity innovation as countries around the world invest in their own longevity ecosystems, and why creating the right incentives today could determine who leads the next generation of medicine. In this episode, you’ll learn: Why public policy may become the biggest accelerator, or bottleneck, for longevity science.How a proposed multi-disease therapeutic designation could speed the development of aging interventions.- Why validated biomarkers and surrogate endpoints are essential for future FDA approval pathways.How Right to Try legislation could expand safe access to experimental longevity therapies while generating valuable clinical data.Why stronger NIH investment, regulatory reform, and grassroots advocacy are all needed to bring longevity medicine into mainstream healthcare. If you want to understand how longevity is evolving from a scientific discipline into a healthcare and public policy movement, this episode explores the people, institutions, and regulatory decisions that could shape the future of healthy aging for decades to come. Subscribe for weekly conversations exploring longevity science, biotechnology, preventative medicine, and the innovations transforming how we live longer and better.

  3. Jul 24

    The First Real Longevity Drugs Are Getting Closer | Longevity News Roundup – Week 30, 2026

    Hosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities. Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off. Link: https://rechargehealthas.sjv.io/jRQyQ5 ---------- In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine major advances in Alzheimer's research, growing investment in national longevity infrastructure, the challenges facing longevity clinics, and why microbiome science is becoming increasingly important for brain and women's health. Biogen and Ionis reported encouraging Phase II results for a tau-targeting Alzheimer's therapy. While the trial missed its primary endpoint, the treatment reduced tau biomarkers and slowed clinical decline, supporting plans for a Phase III study.Lighthouse Pharmaceuticals presented new data showing its gingipain inhibitor reduced agitation, caregiver distress, and cognitive decline in Alzheimer's patients who tested positive for p. gingivalis. The discussion explores what these findings could mean for the growing evidence linking oral health and neurodegeneration.Nova Capital committed $100 million to build a UAE longevity platform integrating clinics, preventive healthcare, digital health, and wellness services. Phil also explores what this investment could signal for the future geography of the global longevity industry.Eternal announced the closure of its longevity clinics, prompting a discussion about why data, defensible technology, and scalable business models may become increasingly important as the sector matures.Juno Bio raised $3.8 million to launch a CLIA-certified sequencing laboratory and expand provider-led vaginal microbiome diagnostics, moving precision women's healthcare beyond traditional symptom-based testing. ---------- News & References: Biogen, Ionis therapy slows early Alzheimer’s progression in Phase 2 trial → https://longevity.technology/news/biogen-ionis-therapy-slows-early-alzheimers-progression-in-phase-2-trial/Lighthouse Pharma’s Alzheimer’s drug reduces agitation, caregiver distress in clinical trial → https://longevity.technology/news/lighthouse-pharmas-alzheimers-drug-reduces-agitation-caregiver-distress-in-clinical-trial/Nova Capital commits $100m to back UAE longevity platform → https://longevity.technology/news/nova-capital-commits-100m-to-back-uae-longevity-platform/Eternal calls time on its longevity clinics → https://longevity.technology/news/eternal-calls-time-on-its-longevity-clinics/Startup Juno Bio raises $3.8m for smarter women’s diagnostics → https://longevity.technology/news/startup-juno-bio-raises-3-8m-for-smarter-womens-diagnostics/

  4. Jul 20

    Are You Taking Too Many Supplements? Gut Health, Blood Tests & Personalized Longevity

    Hosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities. Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off. Link: rechargehealthas.sjv.io/jRQyQ5 ---------- Guests: Aaron Deere Health and Performance Director of HOOKE London LinkedIn: www.linkedin.com/in/aaron-deere-129079128/ Website: www.hooke.london/ Dr Jean-Marc Sobczyk Integrative Medicine & Longevity Physician of HOOKE London LinkedIn: www.linkedin.com/in/jean-marc-sobczyk/ Website: www.hooke.london/ ---------- What if the future of longevity isn't about taking more supplements, but taking fewer, better ones? In this episode, Phil Newman and Dr. Nina Patrick are joined by HOOKE London experts Aaron Deere, Health and Performance Director, and Dr. Jean-Marc Sobczyk, an integrative longevity physician, to explore how personalized nutrition, biomarker testing, and gut health are reshaping the future of preventive healthcare. Drawing on years of clinical experience, they challenge the growing culture of "stacking" supplements without evidence, explaining why many people unknowingly oversupplement certain nutrients while remaining deficient in others. Through real-world case studies, they discuss why comprehensive blood testing should come before supplementation, how personalized formulations outperform generic multivitamins, and why regular monitoring is essential as your health, lifestyle, and physiology evolve over time. The conversation also explores one of the most exciting frontiers in longevity: the microbiome. Aaron and Dr. Sobczyk explain why gut health is far more complex than simply taking probiotics, why the same stool sample can produce completely different results when analyzed by different laboratories, and how emerging AI-powered research could unlock more targeted microbiome therapies for inflammation, cognitive health, mood, skin aging, and disease prevention. Throughout the conversation, one message remains clear: longevity isn't about chasing every new technology or buying every trending supplement. It's about understanding your unique biology and making informed decisions based on data, evidence, and continuous monitoring rather than marketing claims or social media advice. In this episode, you’ll learn: Why taking more supplements can increase the risk of nutrient overload and unnecessary expense.How blood biomarkers can uncover hidden deficiencies like iron, vitamin D, and omega-3 insufficiency while identifying oversupplementation. Why microbiome testing remains useful despite inconsistent laboratory results, and how to interpret those findings in clinical practice. How GLP-1 therapies can support healthspan when combined with strength training, adequate protein intake, and lifestyle change. Why sleep, nutrition, cardiovascular fitness, muscle health, and consistent monitoring still outperform the latest longevity trends. Whether you're building your first supplement protocol or refining an advanced longevity strategy, this conversation offers a practical framework for moving beyond guesswork and toward truly personalised health optimisation. It connects emerging science with real-world clinical experience, showing why testing, monitoring, and individualisation are becoming the new foundation of preventive medicine. Subscribe for weekly episodes exploring longevity science, precision medicine, preventative healthcare, and the innovations shaping how we live longer, healthier lives.

  5. Jul 17

    Is Longevity Becoming the Next Global Race? | Longevity News Roundup — Week 29, 2026

    Hosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities. Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off. Link: rechargehealthas.sjv.io/jRQyQ5 ---------- In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine BioAge's inflammation therapy, Alzheimer's advances, China's growing biotech influence, protein repair research, menopause science and US longevity policy. BioAge dosed the first patient in the Phase 2 QUELL-CV trial of BGE-102, an oral NLRP3 inflammasome inhibitor discovered through human longevity datasets rather than traditional disease-first drug discovery.Alzheon presented new analyses showing reduced brain swelling, preserved brain structure and encouraging biomarker and cognitive signals for valiltramiprosate, despite the original Phase 3 trial missing its primary endpoint. Confirmation studies are still needed.Kailera licensed its entire GLP-1 pipeline from China's Jiangsu Hengrui, highlighting growing US concerns over China's expanding role in drug innovation and obesity therapeutics.Revel Pharmaceuticals enzymatically removed advanced glycation end product (CML) damage from aged human tissues ex vivo, challenging long-held assumptions that some forms of molecular aging are irreversible.Elysium reported early pilot data suggesting its NAD+ supplement Basis reduced several menopause symptoms within seven days while also shifting estrogen metabolism biomarkers. Larger randomized trials are now needed.US policymakers and regulators outlined new frameworks supporting geotherapeutics, aging biomarkers and reimbursement, signalling growing federal momentum behind healthspan-focused medicine. ---------- News & References: BioAge doses first patient in Phase 2 trial of new cardiovascular drug → https://longevity.technology/news/bioage-doses-first-patient-in-phase-2-trial-of-new-cardiovascular-drug/Fresh analyses reshape Alzheon’s oral Alzheimer’s drug → https://longevity.technology/news/fresh-analyses-reshape-alzheons-oral-alzheimers-drug/Kailera’s oral obesity pill posts Phase 3 gains → https://longevity.technology/news/kaileras-oral-obesity-pill-posts-phase-3-gains/When irreversible no longer means forever → https://longevity.technology/news/when-irreversible-no-longer-means-forever/Elysium pilot study links Basis to reduced menopause symptoms → https://longevity.technology/news/elysium-pilot-study-links-basis-to-reduced-menopause-symptoms/US longevity policy takes center stage in Washington → https://longevity.technology/news/us-longevity-policy-takes-center-stage-in-washington/

  6. Jul 13

    The Genetic Clues That Could Predict How You Age

    Hosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities. Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off. Link: rechargehealthas.sjv.io/jRQyQ5 ---------- Guests: Professor Ronjon Nag, OBE President of the R42 Group, CEO and Founder of Agemica and Board Advisor at Genomelink and YourRoots LinkedIn: www.linkedin.com/in/ronjonnag/ Website: www.r42group.com/, agemica.com, app.superbio.ai, genomelink.io, yourroots.com ---------- What if your DNA and AI could become one of the most powerful tools for preventing disease, optimizing health, and extending healthy lifespan? Phil Newman and Dr. Nina Patrick sit down with Ronjon Nag, OBE, President of R42, CEO of Aegemica and Superbio.ai, and Adjunct Professor in Genetics at the Stanford School of Medicine, to explore how artificial intelligence is reshaping genomics and why we're entering a new era of personalized healthcare. Ronjon explains why most diseases are far more complex than single-gene mutations, and why understanding biology increasingly requires combining genetics with biomarkers, clinical records, lifestyle, and AI. He shares why genetics should be viewed as a lifelong health blueprint rather than a one-time report, and how future AI systems may allow people to interact with their own biology in entirely new ways. The conversation also explores why medicine is shifting toward prediction rather than reaction, how AI is helping researchers identify disease patterns hidden inside massive biological datasets, and why better data could dramatically accelerate drug discovery and preventative healthcare. Ronjon also discusses one of his boldest projects yet: developing peptide-based vaccines that target multiple aging pathways simultaneously. By combining AI with large-scale biological datasets, his team hopes to train the immune system to recognize and eliminate damaged cells before they contribute to age-related disease. In this episode, you’ll learn: Why most diseases are influenced by thousands of genes, not just oneHow AI is making genetics more useful for everyday healthcare Why combining genetics with biomarkers creates better health insights How preventative medicine is moving toward personalized risk prediction The science behind peptide vaccines targeting aging pathways Why AI may soon let you "talk" to your own biology If you're interested in AI, biotechnology, longevity science, and the future of healthcare, this episode offers an inside look at the technologies that could fundamentally change how we prevent disease and extend healthy lifespan. Subscribe for weekly conversations exploring longevity science, biotechnology, and the innovations helping people live healthier, longer lives.

  7. Jul 10

    Is Luxury Longevity Coming to an End? | Longevity News Roundup — Week 28, 2026

    Hosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities. Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off. Link: rechargehealthas.sjv.io/jRQyQ5 ---------- In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine mRNA plaque reversal, affordable longevity clinics, laser-driven skin rejuvenation, immune rejuvenation, cuffless blood pressure monitoring, and peptide evidence. Repair Biotechnologies received FDA pathway eligibility for its investigational mRNA therapy targeting intracellular cholesterol, a novel approach that aims to reverse arterial plaque rather than simply lower LDL or slow cardiovascular disease progression.Fountain Life launched a new $595 annual membership, signaling a strategic shift beyond luxury longevity medicine toward employer benefits, insurance integration, and broader access to advanced preventive care. Researchers from Nature’s Scientific Reports has found that Candela’s Nordlys fractional laser treatment produced sustained epigenetic changes associated with younger skin biology, raising the possibility that aesthetic procedures could influence the biology of aging rather than just appearance. United Therapeutics acquired Thymmune Therapeutics for $140 million, highlighting growing confidence in thymus regeneration, immune rejuvenation, and the commercial potential of therapies targeting age-related immune decline. Sky Labs presented its ring-type cuffless blood pressure monitor, CART BP pro, that has entered a large Korean cohort study, potentially making continuous cardiovascular monitoring more practical than traditional inflatable cuffs. Evipedia launched transparent, AI-supported evidence reviews covering 24 peptides, providing clinicians and consumers with an up-to-date resource as regulators continue scrutinizing peptide safety, efficacy, and clinical evidence. ---------- News & References: Repair Bio advances plaque regression program with FDA nod → https://longevity.technology/news/repair-bio-advances-plaque-regression-program-with-fda-nod/Fountain Life makes longevity accessible with $595 membership → https://longevity.technology/news/fountain-life-makes-longevity-accessible-with-595-membership/Laser treatment found to reverse skin aging markers → https://longevity.technology/news/laser-treatment-found-to-reverse-skin-aging-markers/United Therapeutics buys Thymmune Therapeutics for $140m → https://longevity.technology/news/united-therapeutics-buys-thymmune-therapeutics-for-140m/Evipedia expands evidence reviews to cover peptides → https://longevity.technology/news/evipedia-expands-evidence-reviews-to-cover-peptides/ Sky Labs’ blood pressure ring adopted for large-scale national health study → https://longevity.technology/news/sky-labs-blood-pressure-ring-adopted-for-large-scale-national-health-study/

  8. Jul 6

    This AI Can Detect Disease Before Symptoms

    Hosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: Viome Viome is a personalized health platform that uses RNA analysis and AI to provide insights into your microbiome, cellular health, and nutrition. By identifying what's happening inside your body in real time, Viome delivers tailored food, supplement, and lifestyle recommendations designed to support your long-term health and wellness journey. Click the link below to learn more. Link: viomehq.sjv.io/BX74XL ---------- Guests: Naveen Jain Founder and CEO at Viome Life Sciences Instagram: www.instagram.com/naveenjainceo/?hl=en Website: www.viomelifesciences.com/ ---------- What if the biggest breakthrough in longevity isn't changing your DNA, but understanding what your genes are doing right now? Phil Newman and Dr. Nina Patrick sit down with Naveen Jain, entrepreneur, innovator, and founder of Viome, to explore why RNA biology, AI, and the microbiome are reshaping the future of preventative healthcare. While DNA tells us what is possible, Jain argues that RNA reveals what is actually happening inside the body in real time, creating opportunities to detect dysfunction years before symptoms appear. From analyzing more than 400 quadrillion biological data points across 1.5 million biological samples to using AI to interpret millions of microbial and human gene expression signals, the conversation explores how precision diagnostics are moving beyond traditional blood testing. Jain explains why two people can eat the same foods and experience completely different biological outcomes, why there may be no such thing as a universally healthy food, and how personalized nutrition could become one of the most powerful tools for extending healthspan. The discussion also examines the rise of longevity medicine, the consumerization of healthcare, the growing role of AI in clinical decision making, and why early disease detection may become one of the defining advances of this decade. Jain shares how Viome is developing RNA-based diagnostics for conditions including oral cancer, pancreatic cancer, inflammatory bowel disease, and metabolic dysfunction, while also discussing the importance of scientific validation and evidence-based recommendations. In this episode, you’ll learn: How AI can interpret millions of biological signals that humans cannot analyze manually.Why personalized nutrition may outperform generalized dietary advice. How the microbiome influences inflammation, metabolism, cognition, and biological aging. Why foods like broccoli, spinach, avocado, almonds, and red meat can produce very different effects depending on your biology.How Viome's research is advancing early detection for pancreatic cancer, oral cancer, and metabolic disease. If you want to understand how AI, molecular biology, and the microbiome are changing the future of preventative medicine, this episode connects cutting-edge science with practical insights for extending healthspan and longevity. Subscribe for weekly episodes exploring longevity science, preventative medicine, and the innovations shaping how we live longer and better.

Ratings & Reviews

5
out of 5
4 Ratings

About

Longevity.Technology UNLOCKED brings together science, business, and human potential to explore the frontier of longer, healthier living. 🎙 Mondays: In-depth conversations with scientists, founders, investors, operators, and elite performers shaping the longevity ecosystem. 🧠 Fridays: A sharp weekly round-up of the biggest stories, trends, and insights from across the longevity space. If you’re curious about the future of health, performance, and lifespan, this is where it gets UNLOCKED.